Hereditary transthyretin amyloidosis (ATTR) treatment strategies: best practices and emerging therapies
Cost: FreeView Offer chevron_right
Transthyretin amyloidosis (ATTR) is a progressive, multisystem, life-threatening disorder characterized by the extracellular deposition of misfolded, insoluble amyloid fibrils.
After completing Hereditary transthyretin amyloidosis (ATTR) treatment strategies: best practices and emerging therapies physicians will better be able to:
- Describe the pathophysiology of ATTR such that it might inform treatment mechanisms
- Describe available therapies used for treatment of ATTR and explain current literature supporting use of those therapies
- Design and implement an appropriate therapeutic plan for treatment of ATTR
- Describe future therapies currently being investigated for the treatment of ATTR
Target Audience: neurologists, cardiologists, and hematologists; physician assistants, nurse practitioners, nurses, and pharmacists in the aforementioned areas of specialty; and any other HCPs with an interest in or who may clinically encounter patients with ATTR.